Cabaletta Bio, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2019. The filing was signed December 5, 2019. Cabaletta Bio is a clinical-stage biotechnology company developing engineered CAAR T-cell therapies for B-cell-mediated autoimmune diseases. The company had no approved products and no product revenue.
Business Context and Development Status
- Lead candidate DSG3-CAART targets mucosal pemphigus vulgaris. The FDA accepted the company’s IND in September 2019, and management planned to initiate a Phase 1 trial in 2020.
- Additional candidates included MuSK-CAART, DSG3/1-CAART and FVIII-CAART, which remained in discovery or preclinical development.
- The company relied substantially on the University of Pennsylvania and affiliated institutions for research, manufacturing and other development services.
Financial Highlights
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.2 million | $8.6 million |
| General and administrative expense | $1.8 million | $4.2 million |
| Total operating expenses | $5.0 million | $12.8 million |
| Loss from operations | $(5.0) million | $(12.8) million |
| Interest income | $0.4 million | $1.3 million |
| Net loss | $(4.7) million | $(11.5) million |
| Net loss attributable to common stockholders | $(4.7) million | $(16.9) million |
| Net loss per share, basic and diluted | $(2.17) | $(9.34) |
There was no meaningful revenue or profit margin to report because the company had no product sales. The nine-month net loss attributable to common stockholders included a $5.3 million deemed dividend related to an exchange of convertible preferred stock.
Cash, Liquidity and Capitalization
- Cash and cash equivalents were $71.0 million at September 30, 2019, compared with $33.0 million at December 31, 2018.
- Nine-month cash used in operating activities was $8.2 million, compared with $2.8 million in the prior-year period. Investing cash use was $0.4 million, primarily for property and equipment.
- Financing activities provided $46.6 million, including $50.0 million of Series B preferred stock proceeds, offset by issuance costs and deferred IPO costs.
- Accumulated deficit was $27.6 million, compared with $12.5 million at December 31, 2018. Stockholders’ deficit was $26.1 million.
- No convertible notes were outstanding at September 30, 2019; the 2018 notes had converted into preferred stock in October 2018. The filing does not report other material debt outstanding at quarter-end.
- The company stated that approximately $71.0 million of net IPO proceeds received in October and November 2019, together with September 30 cash, was expected to fund operations and capital expenditures through at least the first quarter of 2022. The company had no committed credit facility.
Material Changes Versus Prior Comparable Period
- Third-quarter R&D expense increased $0.6 million to $3.2 million, primarily due to additional personnel, development services and initial Phase 1 start-up costs; this was partly offset by lower intellectual-property licensing and manufacturing costs.
- Nine-month R&D expense increased $5.4 million to $8.6 million as sponsored research, manufacturing, personnel and development activities expanded.
- Third-quarter G&A expense increased $1.3 million to $1.8 million, and nine-month G&A expense increased $3.3 million to $4.2 million, driven by personnel, professional services and public-company preparation costs.
- The prior-year periods included a $6.2 million fair-value adjustment expense on convertible notes; no comparable adjustment was recorded in 2019. This reduced the apparent year-over-year increase in the nine-month net loss.
- Subsequent to quarter-end, the company completed its IPO of 6.8 million shares at $11.00 per share, receiving net proceeds of $66.2 million. In November 2019, underwriters purchased an additional 475,501 shares for approximately $4.9 million of net proceeds. Convertible preferred stock converted into common stock in connection with the IPO.
Outlook, Commitments and Key Risks
- Management expected operating losses, negative cash flows, R&D expenses, G&A expenses and capital expenditures to continue increasing for the foreseeable future.
- The company expected to require additional financing to complete clinical development and commercialize any successful product candidates. Additional equity financing could dilute existing holders, while debt or collaborations could impose restrictions or require relinquishing rights.
- The company committed to fund Penn-sponsored research through April 2021 at an estimated total cost of $8.5 million. The Penn license also includes potential milestone payments approaching $20.0 million, low-single-digit royalties on product sales and sublicense-income obligations.
- Operating lease commitments totaled $0.8 million as of September 30, 2019, with the lease running through July 2022.
- Material risks include failure of preclinical or clinical studies, patient enrollment and trial delays, serious adverse events such as cytokine release syndrome or neurotoxicity, uncertain regulatory requirements, manufacturing and supply constraints, dependence on Penn and other third parties, intellectual-property disputes, and inability to raise additional capital.
- The filing disclosed a 2019 phishing incident involving certain employee email accounts. Management stated that it had no material impact on the business or financial condition, while noting continuing cybersecurity risk.
- The company reported no material litigation or legal proceedings. Management concluded that disclosure controls and procedures were effective at a reasonable assurance level and reported no material change in internal control over financial reporting during the period.
Investor Verification Points
- Verify the conversion of preferred stock, IPO proceeds, post-IPO share count and the effect of the non-voting common stock structure on voting power and dilution.
- Reconcile the stated cash runway through the first quarter of 2022 with actual quarterly cash burn, clinical-trial spending and manufacturing commitments.
- Track the timing, design, enrollment and safety data of the DSG3-CAART Phase 1 trial and any FDA requirements concerning dose escalation or review of Part A data.
- Review Penn license milestones, royalties, sponsored-research obligations and the company’s dependence on Penn for manufacturing and clinical support.
- Assess future financing needs, potential dilution and whether the company can transition manufacturing from Penn to qualified contract manufacturers.